Myron Czuczman, MD

PrintE-mail
Professor of Oncology
Head, Lymphoma/Myeloma Service, Department of Medicine
Head, Lymphoma Translational Research Laboratory, Department of Immunology
Roswell Park Cancer Institute
Professor of Medicine
Senior Member, Graduate Faculty (Immunology)
School of Medicine and Biomedical Sciences, State University of New York at Buffalo

Profile

Areas of Expertise: 
Chronic lymphocytic leukemia
Hodgkin lymphoma
Non-Hodgkin lymphoma
Multiple myeloma
Waldenstrom’s macroglobulinemia
MGUS
Biography: 

Dr. Myron S. Czuczman joined the staff of Roswell Park Cancer Institute in 1992, as attending physician, Department of Medicine, and was appointed Head of the Lymphoma/Myeloma Service in 1998 and became a member of the Tumor Immunology Program in 2002 where he heads a Lymphoma Translational Research Laboratory in the Department of Immunology funded by NIH, State, and philanthropic grants. He is also a Professor of Oncology at Roswell Park Cancer Institute and a Professor of Medicine at the University at Buffalo (UB) School of Medicine and Biomedical Sciences. 

Dr. Czuczman earned his medical degree from Pennsylvania State University College of Medicine in 1985.  He completed internship and residency training at Cornell’s North Shore University Hospital/Memorial Sloan-Kettering Cancer Program (1985-1988).  Between 1988 and 1992, Dr. Czuczman completed a fellowship in Medical Oncology/Hematology and a senior research fellowship in Hematopoietic Cancer Immunochemistry at Memorial Sloan-Kettering Cancer Center, New York, NY.  Dr. Czuczman is licensed by New York State, certified by the American Board of Medical Oncology and is a Diplomate in Internal Medicine.     

Lymphoma research interests focus on monoclonal antibodies either alone or in combination with other agents in the treatment of lymphoma, evaluating novel target-specific molecules active against lymphoma in the clinic and laboratory, and studying the mechanisms-of-action and resistance pathways involving monoclonal antibodies and other novel agents currently used in the treatment of lymphoid neoplasms.  His clinical research has contributed to approval by the U.S. Food and Drug Administration of the first monoclonal therapy - rituximab - for non-Hodgkin’s lymphoma in 1997.  He was the first investigator to publish on the ability to successfully combine rituximab with standard chemotherapy in 1999 which was the “springboard” for additional research which changed the standard treatment approach of mature B-cell neoplasms from chemotherapy-based to immunochemotherapy-based world-wide.

Dr. Czuczman’s Lymphoma Translational Research Laboratory was the first to develop and extensively characterize “rituximab-resistant” cell lines by which the “acquirement” of resistance was associated with a significant decrease in expression of “target” protein (i.e. CD20), as well as an unexpected changes in the balance of apoptotic proteins which made the cells resistant to anti-lymphoma chemotherapy drugs.  His lab is actively evaluating 2nd-generation anti-CD20 antibodies (e.g. veltuzumab, ofatumumab, etc.), and several novel agents in development for the treatment of lymphoma.  In addition, his laboratory is also involved in evaluating the importance of proteasome inhibition with respect to its impact on lymphoma resistance as part of a NIH-funded R01 grant.  He also is interested in the study of tumor microenvironment and its potential as a target for lymphoma therapy.  Lenalidomide (aka Revlimid) and pomalidomide are being studied in his laboratory and he is the PI of a global Phase II/III randomized (FDA registrational) trial of lenalidomide salvage therapy in patients with relapsed/refractory diffuse large B-cell lymphoma.

Dr. Czuczman is a member of the American Association of Cancer Research, the American Society of Hematology and the American Society of Clinical Oncology.  He also serves on the National Comprehensive Cancer Network (NCCN) Lymphoma Guidelines Panel, the NCCN non-Hodgkin’s Lymphoma Outcomes Database Panel and is a cadre member of the Lymphoma Committee of the Cancer and Leukemia Group B (CALGB) national cooperative group.

Dr. Czuczman has authored or co-authored more than 380 journal publications, book chapters and abstracts.  He is a journal reviewer for the Journal of Clinical Oncology, Cancer, Clinical Cancer Research, Blood, Cancer Investigation, Annals of Hematology, Cancer Research, American Journal of Hematology, American Journal of Oncology Review, Oncology, Clinical Lymphoma, and British Journal of Haematology.  He is also on the Editorial Board of The American Journal of Oncology Review, NHL Updates (Darwin Medical Communications), Targeted Therapies, Current Hematologic Malignancy Reports, Clinical Lymphoma and Myeloma, Therapeutic Advances in Hematology, and Expert Opinion on Biological Therapy. 

 Dr. Czuczman is recognized as a leader in the field of novel targeted therapies for NHL and related neoplasms and has lectured both nationally and internationally on this topic.  

 

Research

Research Interests: 
Monoclonal antibodies and cutting-edge novel targeted therapies either alone or in combination with other agents in the treatment of lymphoid neoplasms
Evaluating the significance of minimal residual disease in lymphoid malignancies

Background Information

Education and Training: 
MD - Pennsylvania State University College of Medicine, Hershey, PA
Residency: 
North Shore University Hospital, Manhassett, NY
Board Certification: 
Internal Medicine, Diplomate, American Board of Internal Medicine
Medical Oncology, American Board of Internal Medicine
Fellowships: 
Memorial Sloan-Kettering Cancer Center, New York, NY

Publications

Publications: 
  • Advani A, Schuler M, Sierra J, Smith MR, Verhoef G, Winter JN, Boni J, Vandendries E, Shapiro M, Schmidt-Wolf IG, Rohatiner A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E, Gisselbrecht C, Ketterer N, Nasta S, Fayad L. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. Journal of clinical oncology 2010; 28(12):2085-2093
  • Bhat S, Czuczman MS. Galiximab: a review. Expert opinion on biological therapy 2010; 10(3):451-458
  • Czuczman MS. Novel targeted agents and monoclonal antibodies for aggressive B-cell lymphoma. Clinical advances in hematology and oncology : H&O 2010; 8(1 Suppl. 2):7S-9S
  • Rummel MJ. Q&A discussion of select presentations with. Clinical advances in hematology and oncology : H&O 2010; 8(2):4-11
  • Rummel MJ. Recent advances in NHL: Highlights from the 51st ASH annual meeting and exposition, December 5-8, 2009, New Orleans, Louisiana. Clinical advances in hematology and oncology : H&O 2010; 8(2):1-3
  • Czuczman MS, Gregory SA. The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leukemia and lymphoma 2010; 51(6):983-994
  • Elefante A, Czuczman MS. Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia. American journal of health-system pharmacy : AJHP 2010; 67(9):713-723
  • Kahl BS, Van Der Jagt RH, Joyce R, Robinson KS, Czuczman MS, Williams ME, Ganjoo K, Chen L, Leonard JP, Bartlett NL, Cheson BD. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer 2010; 116(1):106-114
  • Riaz W, Hernandez-Ilizaliturri FJ, Czuczman MS. Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms. Immunologic research 2010; 46(1-3):192-205
  • Sher T, Lee K, Block AW, Wood MT, Sood R, Bilgrami SA, Lawrence W, Miller A, Czuczman MS, Hernandez-Ilizaliturri F, Whitworth A, Lawrence D, Miller KC, Chanan-Khan AA. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leukemia and lymphoma 2010; 51(1):85-88
  • Czuczman M, Ervin-Haynes A, Polikoff J, Bouabdallah R, Haioun C, Buckstein R, Reeder C, Zinzani PL, Vose J, Witzig T. Lenalidomide monotherapy is clinically active in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL): A pooled analysis of data from 2 phase II studies (NHL-002/003). Haematologica 2010; 95(Suppl. 2):Abstract #574
  • Czuczman M, Straus D, Gribben J, Bredenfeld H, Friedberg J, Bollard C. Management options, survivorship, and emerging treatment strategies for follicular and Hodgkin lymphomas. Leukemia and lymphoma 2010; 51(Suppl. 1):41-49
  • Czuczman MS, Gregory SA, van Der Jagt R. B-cell non-hodgkin lymphoma: A case-based discussion of recent advances in patient management. Clinical advances in hematology and oncology : H&O 2010; 8(7 Suppl. 13):1-15
  • Czuczman S, Windfeld K, Lin T, Gupta I, Trumper L, Pytlik R, Mayer J, Pohlman B, Gregory S, Belada D, Pedersen L, Hansen P, Gadeberg O, Hess G, Viardot A, Russell C. Ofatumumab in combination with CHOP (0-CHOP) achieves high response rates in previously untreated follicular lymphoma (FL) patients with high-risk FLIPI scores. Haematologica 2010; 95(Suppl. 2):Abstract #273
  • Reddy N, Czuczman MS. Enhancing activity and overcoming chemoresistance in hematologic malignancies with bortezomib: preclinical mechanistic studies. Annals of oncology 2010; 21(9):1756-1764
  • Verhoef G, Boni J, Vandendries E, Hua S, Durrant S, Foran J, Czuczman M, Coiffier B, Gine E, Kaufman J, Rohatiner A, Johnson P, Offner F, Smith M, Dang N, Fayad L. Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab: Clinical activity in patients with relapsed/refractory follicular or 'aggressive' lymphoma. Haematologica 2010; 95(Suppl. 2):Abstract #573
  • Wilson H, Krivoshik P, Enschede H, Busman T, Chiu YL, Xiong H, Tulpule A, Leonard P, Gerecitano F, LaCasce S, Czuczman S, O'Connor A, Humerickhouse H. Phase 1/2a study of navitoclax (ABT-263) in relapsed or refractory lymphoid malignancies. Haematologica 2010; 95(Suppl. 2):Abstract #292
  • Zinzani PL, Ervin-Haynes A, Piertronigro D, Li J, Polikoff J, Buckstein R, Reeder C, Vose J, Witzig T, Czuczman M. Lenalidomide has clinical activity and induces durable responses in patients with transformed lymphoma: Subset analysis of an international phase 2 study (NHL-003) in aggressive non-Hodgkin's lymphoma. Haematologica 2010; 95(Suppl. 2):Abstract #686
  • Czuczman MS, Leonard JP, Williams ME. Recent advances in the treatment of mantle cell lymphoma: a post-ASH 2009 discussion. Clinical advances in hematology and oncology : H&O 2010; 8(4 Suppl. 8):A1-A14; quiz A15
  • Czuczman MS, Rummel MJ. Clinical Roundtable Monograph: recent advances in NHL. Highlights from the 51st ASH Annual Meeting and Exposition, December 5-8, 2009, New Orleans, Louisiana. Clinical advances in hematology and oncology : H&O 2010; 8(2 Suppl. 3):A1-A11
  • Czuczman MS. Unmet needs in the treatment of aggressive lymphoma. Clinical advances in hematology and oncology : H&O 2010; 8(10):7-8
  • Wilson WH , Enschede SH , Krivoshik AP , Rosenberg SH , Elmore SW , Busman T , Cui Y , Chiu Y-L , Xiong H , Dunleavy K , Tulpule A , Leonard JP , Gerecitano JF , LaCasce AS , Czuczman MS , O'Connor OA , Humerickhouse RA. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet oncology 2010; 11(12):1149-1159
  • Younes A , Fox NL , Kumm E , Miceli R , Halpern W , Klein J , Ansell SM , Burris HA , Smith MR , Zelenetz AD , Vose JM , Czuczman MS. A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma. British journal of cancer 2010; 103(12):1783-1787
  • Oliansky DM, McCarthy PL Jr, Jones RB, Wolff SN, Vose J, Omel J, Lazarus HM, Irwin FD, Fisher RI, Czuczman M, Hahn T. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. Biology of blood and marrow transplantation 2011; 17(1):20-47.e30
  • Abou-Nassar KE, Zelenetz AD, Gordon LI, Crosby A, Millenson M, Czuczman MS, Rodriguez MA, Niland J, Abel G, Friedberg JW, Vanderplas A, LaCasce A. Patterns of use of FDG-PET for the initial staging of follicular lymphoma (FL) and its impact on initial treatment strategy and outcomes in the national comprehensive cancer network (NCCN) lymphoma database. Blood 2010; 116(21):81
  • Barth M, Hernandez-Ilizaliturri FJ, Mavis C, Tsai P, Gibbs J, Deeb G, Czuczman MS. Ofatumumab, a fully human monoclonal antibody targeting CD20, demonstrates activity against and potentiates the anti-tumor activity of chemotherapy agents in rituximab-sensitive cell lines (RSCL), rituximab-resistant cell lines (RRCL), lymphoma xenografts, and primary tumor cells derived from patients with B-cell non-hodgkin lymphoma (NHL). Blood 2010; 116(21):3917
  • Gu J, Hernandez-Ilizaliturri FJ, Kaufman GP, Mavis C, Czuczman MS. Carfilzomib (CFZ): A novel proteasome inhibitor that induces cell cycle arrest and cell death in rituximab-chemotherapy resistant lymphoma and potentiates the anti-tumor activity of chemotherapeutic agents. Blood 2010; 116(21):4908
  • Gu J, Ritesh P, Mavis C, Deeb G, Gibbs J, Hernandez-Ilizaliturri FJ, Czuczman MS. MLN2238, a novel and potent proteasome inhibitor, induces caspase-dependent cell death, cell-cycle arrest, and potentiates the anti-tumor activity of chemotherapy agents in rituximab-chemotherapy sensitive or resistant B-cell lymphoma cell lines. Blood 2010; 116(21):3939
  • Hernandez-Ilizaliturri FJ, Mavis C, Maraj I, Chisti MM, Gibbs J, Czuczman MS. Panobinostat, a novel histone deacetylase (HiDAC) inhibitor enhances the anti-tumor activity of bortezomib (BTZ) in rituximab-chemotherapy sensitive and resistant lymphoma cell lines. Blood 2010; 116(21):3936
  • Kumar A, Friedberg JW, Zelenetz AD, Millenson M, Gordon LI, Niland J, Nademanee A, Czuczman MS, Lepisto E, Crosby AL, Rodriguez MA, LaCasce AS, Vanderplas A, Abel GA. Incidence, method and covariates of central nervous system (CNS) prophylaxis for diffuse large B-cell lymphoma in the national comprehensive cancer network (NCCN) lymphoma database. Blood 2010; 116(21):1756
  • Love N, Gregory SA, Cheson BD, Czuczman MS, Elder M, Paley D, Ziel K. Tolerance and response to initial systemic therapy in older patients with follicular lymphoma (FL): Observations from 186 unselected recent cases in the practices of US-based medical oncologists (MOs). Blood 2010; 116(21):3842
  • Stein R, Chen S, Hernandez-Ilizaliturri FJ, Czuczman MS, Goldenberg DM. Milatuzumab improves efficacy of current treatments for B-cell malignancies. Blood 2010; 116(21):2837
  • Tsai P, Dvorak P, Bangia N, Olejniczak S, Czuczman MS, Hernandez-Ilizaliturri FJ. Rituximab resistance is associated with global downregulation of CD20 and CD54 in B-cell lymphoma cells: Implication of CD20 signaling on CD54. Blood 2010; 116(21):5077
  • Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai P, Gibbs JF, Czuczman MS. Activity of ofatumumab (OFA), a fully human monoclonal antibody targeting CD20, against rituximab (RTX)-sensitive (RSCL) and rituximab-resistant cell lines (RRCL), in vivo, and primary tumor cells derived from patients with B-cell lymphoma. Journal of clinical oncology 2010; 28(15 Suppl.):8095
  • Belada D, Mayer J, Czuczman MS, Flinn IW, Durbin-Johnson B, Bray GL. Phase II study of dulanermin plus rituximab in patients with relapsed follicular non-Hodgkin's lymphoma (NHL). Journal of clinical oncology 2010; 28(15 Suppl.):8104
  • Czuczman MS, Windfeld K, Strange C, Lin TS, Gupta I, Pedersen LM, Gadeberg OV, Hess G, Viardot A, Russell CA. Ofatumumab combined with CHOP in previously untreated patients with follicular lymphoma (FL). Journal of clinical oncology 2010; 28(15 Suppl.):8042
  • Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, Macon WR, Witzig TE, Goy A, Czuczman MS. Response of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with nongerminal center B-cell phenotype to lenalidomide (L) alone or in combination with rituximab (R). Journal of clinical oncology 2010; 28(15 Suppl.):8038
  • Kaufman GP, Hernandez-Ilizaliturri FJ, Mavis C, Patil R, Czuczman MS. Evaluation of carfilzomib to disrupt the apoptotic threshold of B-cell lymphomas by targeting Bcl-2 family members and overcome rituximab (R) chemotherapy resistance. Journal of clinical oncology 2010; 28(15 Suppl.):e18514
  • Lamonica DM, Hahn T, Drumsta D, Achakzai M, Czuczman MS, Hernandez-Ilizaliturri FJ. 18F-fluorodeoxglucose (FDG) positron emission tomography (PET) versus FLIPI as a predictor of therapy response in follicular lymphoma (FL) patients. Journal of clinical oncology 2010; 28(15 Suppl.):8102
  • Patil R, Hernandez-Ilizaliturri FJ, Elefante A, Czuczman MS. Body mass index (BMI) and obesity as a predictor of clinical outcome in patients with Hodgkin's lymphoma treated with AVBD. Journal of clinical oncology 2010; 28(15 Suppl.):8063
  • Reeder CB, Ervin-Haynes AL, Pietronigro D, Li J, Polikoff J, Buckstein R, Zinzani PL, Witzig TE, Vose J, Czuczman MS. Lenalidomide (LEN) in patients with transformed lymphoma: Results from a large international phase II study (NHL-003). Journal of clinical oncology 2010; 28(15 Suppl.):8037
  • Riaz W, Hernandez-Ilizaliturri FJ, Mavis C, Tsai P, Czuczman MS. Efficacy of combination of rituximab (R), obatoclax (O), and bortezomib (B) against rituximab-sensitive (RSCL) and rituximab-resistant B-cell lymphoma cell lines (RRCL). Journal of clinical oncology 2010; 28(15 Suppl.):8094
  • Chavez J, Czuczman MS, Hernandez-Ilizaliturri FJ. Biology and management of diffuse large B-cell lymphoma. Contemporary oncology 2010; 2(1):28-38
  • Olejniczak SH, Hernandez-Ilizaliturri FJ, Gibbs J, Clements JL, Mavis C, Riaz W, Bangia N, Belicha-Villanueva A, Blickwedehl J, Czuczman MS. Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells. Blood 2010; 116(25):5605-5614
  • Zelenetz AD, Lacasce AS, Mughal TI, Nademanee A, Porcu P, Press O, Prosnitz L, Reddy N, Smith MR, Sokol L, Swinnen L, Vose JM, Wierda WG, Yahalom J, Kim YH, Kaminski MS, Abramson JS, Advani RH, Babis Andreadis C, Byrd JC, Czuczman MS, Fayad L, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Horwitz SM, Yunus F. NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. Journal of the National Comprehensive Cancer Network : JNCCN 2010; 8(3):288-334
  • Bhat SA, Czuczman MS. Novel antibodies in the treatment of non-Hodgkin's lymphoma. Netherlands journal of medicine 2009; 67(8):311-321
  • Chanan-Khan A, Lee K, Iancu D, Patel M, Barcos M, Bernstein ZP, Mohr A, Sher T, Ailawadhi S, Yu J, Padmanabhan S, Musial L, Miller KC, Czuczman MS. Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. Leukemia and lymphoma 2009; 50(7):1096-1101
  • Dunleavy K, Staudt LM, Janik JE, Jaffe ES, Shovlin M, Grant N, Wright G, Dave SS, Czuczman MS, Pittaluga S, Wilson WH. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009; 113(24):6069-6076
  • Goldenberg DM, Rossi EA, Stein R, Cardillo TM, Czuczman MS, Francisco JH-I, Hansen HJ, Chang C-H. Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood 2009; 113(5):1062-1070
  • Hernandez-Ilizaliturri FJ, Czuczman MS. Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 1. current treatment approaches. Oncology (Williston Park, N.Y.) 2009; 23(6):546-553
  • Hernandez-Ilizaliturri FJ, Hernandez-Ilizaliturri FJ, Czuczman MS. Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 2. Novel therapeutic strategies. Oncology (Williston Park, N.Y.) 2009; 23(7):610-615
  • Khubchandani S, Czuczman MS. Targeted therapies in B-cell non-Hodgkin lymphomas. Therapy 2009; 6(3):371-380
  • Khubchandani S, Czuczman MS, Hernandez-Ilizaliturri FJ. Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies. Current opinion in investigational drugs (London, England : 2000) 2009; 10(6):579-587
  • Radich JP, Wetzler M, Sundar HM, Snyder DS, Smith BD, Houldsworth J, Horning SJ, Erba HP, Czuczman MS, Croce CM, Chan WC, Zelenetz AD, Winter JN. NCCN task force report: molecular markers in leukemias and lymphomas. Journal of the National Comprehensive Cancer Network : JNCCN 2009; 7 Suppl. 4:S1-S34, quiz S35-S36
  • Chyla B, Krivoshik A, Enschede S, Gerecitano J, Czuczman M, O'Connor O, Wilson W, Tahir S, Smith M, McKeegan E. Bcl-2 family protein expression in navitoclax-treated patients (pts) with lymphoid malignancies. European journal of cancer (Oxford, England : 1990) 2010; 8(7):192
  • Brem EA, Czuczman MS, Fetterly G, Gibbs JF, Deeb G, Hoskin P, Mavis C, Knight J, Campagna R, Iqbal A, Gu J, Riaz W, Bhat S, Olejniczak SH, Tsai PC, Khubchandani S, Thudium K, Hernandez-Ilizaliturri FJ. Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas. British journal of haematology 2011; 153(5):599-611
  • Chanan-Khan A, Zeldis JB, Wallace PK, Czuczman MS, Hernandez-Illatazurri F, Miller A, Padmanabhan S, Lawrence D, Miller KC, Lee K. Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer 2011; 117(10):2127-2135
  • Sher T, Lee K, Iancu D, Masood A, Jamshed S, Lawrence W, Soniwala S, Sood R, Hong F, Hernandez-Ilizaliturri FJ, Czuczman MS, Wilding G, Tan W, Wood M, Manfredi D, Miller KC, Ailawadhi S, Chanan-Khan A. A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. British journal of haematology 2011; 154(1):104-110
  • Zelenetz AD, Kim YH, Lacasce AS, Nademanee A, Porcu P, Press O, Pro B, Reddy N, Sokol L, Swinnen LJ, Tsien C, Vose JM, Wierda WG, Yahalom J, Kelsey CR, Horwitz SM, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT, Zafar N. Non-Hodgkin's Lymphomas. Journal of the National Comprehensive Cancer Network : JNCCN 2011; 9(5):484-560
  • Benekli M, McCarthy PL Jr, Padmanabhan S, Battiwalla M, Bambach B, Hernandez-Ilizaliturri F, Czuczman MS, Younis T, Smiley SL, Hahn T. Intensive conditioning regimen of etoposide (VP-16), cyclophosphamide and carmustine (VCB) followed by autologous hematopoietic stem cell transplantation for relapsed and refractory Hodgkin's lymphoma. Bone marrow transplantation 2008; 41(7):613-619
  • Czuczman MS, Deans J, Starostik P, Knight J, Kaur H, Binder A, Kotowski A, Gowda A, Olejniczak S, Hernandez-Ilizaliturri FJ. Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clinical cancer research 2008; 14(5):1561-1570
  • LaCasce AS, Zelenetz AD, Millenson MM, Czuczman MS, Rodriguez MA, Abel GA, Niland JC, Friedberg JW, Kho ME, Weeks JC. Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network. Journal of clinical oncology 2008; 26(31):5107-5112
  • Mattes MJ, Sharkey RM, Karacay H, Czuczman MS, Goldenberg DM. Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab). Clinical cancer research 2008; 14(19):6154-6160
  • Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression. Clinical cancer research 2008; 14(5):1550-1560
  • Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J, Wallace P, Czuczman MS. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. British journal of haematology 2008; 140(1):36-45
  • Cai S, Cannizzo F Jr, Bullard Dunn KM, Gibbs JF, Czuczman M, Rajput A. The role of surgical intervention in non-Hodgkin's lymphoma of the colon and rectum. American journal of surgery 2007; 193(3):409-412; discussion 412
  • Czuczman MS, Emmanouilides C, Darif M, Witzig TE, Gordon LI, Revell S, Vo K, Molina A. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. Journal of clinical oncology 2007; 25(27):4285-4292
  • Leonard JP, Finucane D, McKinney B, Chieffo N, Forero-Torres A, Cheson BD, Stiff P, Miller T, Czuczman M, Moore J, Gordon LI, Fisher D, Younes A, Friedberg JW, Molina A. A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Annals of oncology 2007; 18(7):1216-1223
  • Maddipatla S, Hernandez-Ilizaliturri FJ, Knight J, Czuczman MS. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20. Clinical cancer research 2007; 13(15 Pt 1):4556-4564
  • Cruz RI, Hernandez-Ilizaliturri FJ, Olejniczak S, Deeb G, Knight J, Wallace P, Thurberg BL, Kennedy W, Czuczman MS. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma. Leukemia and lymphoma 2007; 48(12):2424-2436
  • Czuczman MS. Sixth International Workshop on non-Hodgkin Lymphoma: 16-17 November 2007, Boston, USA. Leukemia and lymphoma 2008; 49 Suppl. 1:4-6
  • Czuczman MS, Cheson BD, Canellos G, Cook JR, Hsi ED, Kelly M, Niedzwiecki D, Johnson J, Porcu P, Cancer and Leukemia Group B. Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. Leukemia and lymphoma 2007; 48(1):97-103
  • O'Connor OA, Czuczman MS. Novel approaches for the treatment of NHL: Proteasome inhibition and immune modulation. Leukemia and lymphoma 2008; 49 Suppl. 1:59-66
  • Vinjamaram S, Czuczman MS, Hernandez-Ilizaliturri FJ. The use of galiximab in non-Hodgkin lymphoma. Clinical lymphoma and myeloma 2008; 8(5):277-282
  • Bhat SA, Czuczman MS. Humanized anti-CD20 monoclonal antibody oncolytic. Drugs of the future 2011; 36(7):519-526
  • Czuczman MS, Ervin-Haynes A, Pietronigro D, Li J, Polikoff J, Buckstein R, Zinzani PL, Witzig TE, Vose JM, Reeder CB. The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin. British journal of haematology 2011; 154(4):477-481
  • Derby L, Czuczman MS. Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders. Future oncology (London, England) 2011; 7(8):963-979
  • Witzig TE, Ervin-Haynes AL, Pietronigro D, Guo P, Tilly H, Haioun C, Bouabdallah R, Polikoff JA, Buckstein R, Reeder CB, Zinzani PL, Vose JM, Czuczman MS. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Annals of oncology 2011; 22(7):1622-1627
  • Gregory SA, Cheson BD, Czuczman MS, Love N. Management of follicular lymphoma in the up-front and relapsed settings. Oncology (Williston Park, N.Y.) 2010; 24(12):15-23
  • Abel GA, Vanderplas A, Friedberg JW, Niland J, Rodriguez MA, Czuczman MS, Millenson M, Crosby AL, Gordon LI, Blayney DW, Zelenetz AD, LaCasce AS. Variations in Surveillance Imaging for Patients with Treated Diffuse Large B-Cell Lymphoma in the National Comprehensive Cancer Network (NCCN) Lymphoma Database. Blood 2009; 114(22):565
  • Ailawadhi S, Hernandez-Ilizaliturri FJ, Miner L, Bernstein ZP, Chanan-Khan A, Miller KC, Mohr A, Starostik P, Czuczman MS, Padmanabhan S. Differences in BCL-2 protein and t(14;18) in patients with primary Rituximab/Chemotherapy refractory diffuse large B-Cell lymphoma (DLBCL). Blood 2007; 110(11 Part 2):177B (Abstract #4433)
  • Ashraf U, Czuczman MS, Marvis C, Gibbs J, Hernandez-Ilizaliturri FJ. Entinostat (SNDX-275), a Novel DAC Inhibitor, Is Highly Effective in Rituximab- [Chemotherapy]-Sensitive or Rituximab-[Chemotherapy]-Resistant Lymphomas and Has Synergistic Anti-Tumor Activity When Combined with Bortezomib. Blood 2009; 114(22):1435-1436
  • Ashraf U, Elefante AN, Cruz R, Wallace PK, Czuczman MS, Hernandez-Ilizaliturri FJ. Emergence of rituximab-fludarabine resistance is associated with changes in CD20 antigen expression-and improved response to almetuzumab therapy in patients with chronic lymphocytic leukemia (CLL). Blood 2007; 110(11 Part 1):Abstract #2054
  • Ashraf U, Mahajan R, Hahn T, Smiley SL, McCarthy PL, Bernstein ZP, Chanan-Khan AA, Battiwala M, Czuczman MS, Hernandez-Lizaliturri FJ. The Effects of Rituximab Added to Front-Line or Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing High-Dose Chemotherapy (HDC) and Autologous Stem Cell Transplant (ASCT). Blood 2008; 112(11):415-416
  • Chanan-Khan A, Czuczman MS, Padmanabhan S, Keating MJ, O'Brien SM, Wierda WG, Ferrajoli A. Clinical efficacy of lenalidomide in fludarabine-refractory chronic lymphocytic leukemia patients. Blood 2007; 110(11 Part 1):Abstract #3108
  • Chavez J, Walsh M, Hernandez-Ilizaliturri FJ, Elefante A, Czuczman MS. Classification of Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) According to the Han's Criteria Defines Two Groups of Patients with Different Clinical Outcomes Following Systemic Rituximab-Multi Agent Anthracycline-Based Therapy. Blood 2009; 114(22):258
  • Cruz RI, Hernandez-Ilizaliturri FJ, Knight JM, Czuczman MS. CD52 over-expression affects rituximab-associated complement mediated cytotoxicity (CMC) but not antibody dependent cellular cytotoxicity (ADCC): Pre-clinical evidence targeting CD52 with alemtuzumab to reverse acquired resistance to rituximab in Non-Hodg. Proceedings of the American Association for Cancer Research Annual Meeting 2007; 48:980
  • Czuczman MS. The biology of B-cell CD20 antigen and its potential as a therapeutic target. Annals of oncology 2008; 19(Suppl. 4):257
  • Czuczman MS. Update on galiximab: Anti-CD80 monoclonal antibody. Cancer investigation 2007; 25(Suppl. 1):36
  • Czuczman MS, Leonard JP, Johnson JL, Jung SH, Hsi E, Byrd JC, Cheson BD. FLIPI Score Is Applicable and Predictive of Response to Upfront Immunotherapy in CALGB 50402: Phase 11 Trial of Extended Induction Galiximab ([G] anti-CD80 monoclonal antibody) Plus Rituximab [R]. Blood 2008; 112(11):369
  • Czuczman MS, Skipper M, Mohr A, Bernstein ZP, Hernandez-Ilizaliturri FJ, Chanan-Khan AA. Phase I/II study of rituxan (R) in combination with doxil (D) in patients (pts) with relapsing or refractory B-cell lymphoma: Clinical efficacy without cardiac toxicity. Blood 2007; 110(11 Part 1):Abstract #1369
  • Czuczman MS, Vose J, Zinzani P, Reeder C, Buckstein R, Haioun C, Bouabdallah R, Polikoff J, Ervin-Haynes A, Witzig T. Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma: Results from an international study (NHL-003). Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #e19504
  • Czuczman MS, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Haioun C, Bouabdallah R, Polikoff J, Guo PS, Ervin-Haynes A, Pietronigro D, Zeldis JB, Witzig TE. Confirmation of the Efficacy and Safety of Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory Diffuse Large-B-Cell Lymphoma: Results of An International Study (NHL-003). Blood 2008; 112(11):106
  • Dang NH, Smith MR, Offner F, Verhoef G, Johnson P, Rohatiner AZS, Kaufman JL, Gine E, Coiffier B, Czuczman MS, Foran J, Durrant S, Hua S, Vandendries ER, Fayad L. Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) + Rituximab: Clinical Activity Including Survival in Patients with Recurrent/Refractory Follicular or 'Aggressive' Lymphoma. Blood 2009; 114(22):242-243
  • Derby L, Hernandez-Ilizaliturri FJ, Segal BH, Knight J, Bushey J, Czuczman MS. Pegylated granulocyte colony stimulating factor (Peg-G-CSF) enhances mapatumumab-mediated antibody dependent cellular cytotoxicity (ADCC) against non-Hodgkin's lymphoma (NHL) cell lines independent of NADPH oxidase-derived reactive oxidant intermediates (ROIs). Blood 2007; 110(11 Part 2):Abstract #4519
  • Fayad L, Patel H, Verhoef G, Smith MR, Johnson PWM, Czuczman MS, Coiffier B, Hess G, Gine E, Advani A, Offner F, Vandendries ER, Shapiro M, Dang NH. Safety and Clinical Activity of the Anti-CD22 Immunoconjugate Inotuzumab Ozogamicin (CMC-544) in Combination with Rituximab in Follicular Lymphoma or Diffuse Large B-Cell Lymphoma: Preliminary Report of a Phase 1/2 Study. Blood 2008; 112(11):105
  • Ferrajoli A, Keating MJ, Wierda WG, O'Brien SM, Padmanabhan S, Czuczman MS, Chanan-Khan AA. Lenalidomide is active in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) carrying unfavorable chromosomal abnormalities. Blood 2007; 110(11 Part 1):Abstract #754
  • Friedberg JW, Younes A, Fisher DC, Gordon LI, Moore JO, Czuczman MS, Miller TP, Stiff PJ, Cheson BD, Forero-Torres A, McKinney B, Leonard JP. Durable Responses in Patients Treated with Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory Follicular Lymphoma: Long-Term Follow-up of a Phase II Clinical Trial. Blood 2008; 112(11):369-370
  • Gruber EA, Czuczman MS, Olejniczak SH, Knight J, Hernandez-Ilizaliturri FJ. GX15-070 and bortezomib induce up-regulation of BH3 single domain pro-apoptotic proteins Puma and Noxa and is associated with synergistic anti-tumor activity in rituximab-sensitive, rituximab-resistant cell lines (RSCL and RRCL), and primary lymphoma patient specimens. Blood 2007; 110(11 Part 2):417A
  • Gruber EA, Czuczman MS, Olejniczak SH, Knight J, Hernandez-Ilizaliturri FJ. GX15-070 and bortezomib induce up-regulation of BH3 single domain pro-apoptotic proteins Puma and Noxa and is associated with synergistic anti-tumor activity in rituximab-sensitive, rituximab-resistant cell lines (RSCL and RRCL), and primary lymphoma patient specimens. Blood 2007; 110(11 Part 1):Abstract #1389
  • Hagenbeek A, Fayad L, Delwail V, Rossi JF, Jacobsen E, Kuliczkowski K, Link BK, Pinter-Brown L, Radford J, Hellmann A, Gallop-Evans E, Gupta I, Arning M, Begtrup K, Schultz M, Bang B, Russell CA, Czuczman MS. Evaluation of Ofatumumab, a Novel Human CD20 Monoclonal Antibody, as Single Agent Therapy in Rituximab-Refractory Follicular Lymphoma. Blood 2009; 114(22):385-386
  • Hernandez-Ilizaliturri F, Tsio PC, Campagna R, Marvis C, Riaz W, Gruber E, Gibbs J, Czuczman MS. Obatoclax and Bortezomib Therapy Results in Disruption of the p53-Mediated Apoptosis/Autophagy Pathway and Is Associated with Potent Synergistic Anti-Tumor Activity against Rituximab-Chemotherapy-Sensitive and -Resistant B-Cell Lymphoma. Blood 2009; 114(22):121
  • Hernandez-Ilizaliturri FJ, Ali M, Knight J, Rustum YM, Czuczman MS. Methylseleninic acid (MSA) decreases DNA synthesis, induces cell death, and sensitizes both rituximab sensitive and rituximab-resistant non-Hodgkin's lymphoma cell lines to the anti-tumor activity of cisplatin and gemcitabine. Blood 2007; 110(11 Part 2):201B (Abstract #4517)
  • Hernandez-Ilizaliturri FJ, Khubchandani S, Olejniczak SH, Hoskin P, Czuczman MS. Strategies to overcoming rituximab-chemotherapy resistance by targeting the autophagy pathway using bortezomib in combination with the Bcl-2 inhibitor obatoclax in non-Hodgkin's lymphomas (NHL). Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #8543
  • Hernandez-Ilizaliturri FJ, Khubchandani S, Olejniczak SH, Hosking P, Gruber E, Czuczman M. The BH3-Mimetic Obatoclax (GX15-070) Posses a Dual-Mechanism of Action and Induces Both Apoptosis and Autophagy-Dependent Cell Death of B Cell Non-Hodgkin's Lymphoma (B-NHL) Cells. Blood 2008; 112(11):226
  • Hernandez-Ilizaliturri FJ, Marvis C, Maraj I, Chisti MM, Gibbs J, Czuczman MS. The DAC Inhibitor, LBH589, Is Highly Effective in Both Rituximab- Sensitive and Rituximab. Resistant Lymphomas and Enhances the Anti-Tumor Activity of Bortezomib, Other Chemotherapy Agents, and Anti-CD20 Monoclonal Antibodies. Blood 2009; 114(22):1063
  • Kahl B, Bartlett NL, Leonard JP, Ganjoo K, Williams ME, Czuczman MS, Robinson KS, Joyce R, van der Jagt RH, Cheson BD. Bendamustine is safe and effective in patients with rituximab-refractory, indolent B-Cell non-Hodgkin lymphoma. Blood 2007; 110(11 Part 1):Abstract #1351
  • LaCasce A, Vandergrift JL, Rodriguez MA, Crosby AL, Lepisto EM, Czuczman MS, Nademanee AP, Blayney DW, Gordon LI, Millenson M, Vanderplas A, Abel GA, Zelenetz AD, Friedberg JW. R-CHOP, Followed by High Dose Therapy and Autologous Stem Cell Rescue (HDT/ASCR), and R-Hypercvad Have Equivalent Progression-Free Survival and Are Superior to R-CHOP Alone in Younger Patients with Mantle Cell Lymphoma: a Comparative Effectiveness Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma Outcomes Database Project. Blood 2009; 114(22):167-168
  • Maraj I, Hernandez-Ilizaliturri FJ, Chisti M, Czuczman MS. Efficacy of the DAC inhibitor LBH589 in both rituximab-sensitive and rituximab-resistant lymphomas and effect on the antitumor activity of chemotherapy agents, monoclonal antibodies, and bortezomib. Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #8576
  • O'Connor O, Czuczman MS, LaCasce A, Gerecitano J, Leonard JP, Dunleavy K, Krivoshik A, Shovlin M, Narwal A, Xiong H, Chiu Y, Wilson W. A phase 1 study evaluating the safety, PK & efficacy of ABT-263 in subjects with refractory or relapsed lymphoid malignancies. Annals of oncology 2008; 19(Suppl. 4):115-116
  • Olejniczak SH, Czuczman MS, Hoskin P, Gruber E, Hernandez-Ilizaliturri FJ. The BH3-mimetic GX15-070 induces autophagy-dependent cell death of therapy-sensitive and -resistant aggressive B cell non-Hodgkin's lymphoma (B-NHL). Proceedings of the American Association for Cancer Research Annual Meeting 2008; 49:797
  • Olejniczak SH, Hernandez-Ilizaliturri F, Belicha A, Blickwedehl J, Clements JS, Bangia N, Czuczman MS. Bortezomib induces Bak expression and cell death in non-Hodgkin's lymphoma cell lines that are both rituximab- and chemotherapy-resistant. Proceedings of the American Association for Cancer Research Annual Meeting 2007; 48:457
  • Olejniczak SH, Hernandez-Ilizaliturri FJ, Blickwedehl J, Bangia N, Clements JL, Czuczman MS. Bortezomib induces a pro-apoptotic Bcl-2 family protein expression profile necessary to kill therapy-resistant B cell non-Hodgkin's lymphoma (B-NHL). Proceedings of the American Association for Cancer Research Annual Meeting 2008; 49:1043
  • Padmanabhan S, Elefante A, Varadarajan P, Battiwaralla M, Bir A, Hahn T, Smiley S, Hernandez-Illizalitturi FJ, Miner L, Mohr A, Bernstein ZP, Chanan-Khan A, McCarthy P, Czuczman M. Outcomes of relapsed/refractory B-cell lymphoma is improved by salvage chemotherapy consisting of two to three cycles of dexamethasone (D), High Dose Ara-C (HA) and carboplatin (DHAC) with or without rituximab (R) followed by autologous stem cell transplantation. Blood 2007; 110(11 Part 2):364B-365B (Abstract #5130)
  • Ramanarayanan J, Krishnan GS, Czuczman MS, Hernandez-Izaliturri FJ. Efficacy and safety of rituximab in post transplant lymphoproliferative disorders (PTLD): Pooled analysis and review of literature. Blood 2007; 110(11 Part 1):Abstract #1084
  • Reddy N, Hernandez-Ilizaliturri FJ, Knight J, Myron CS. Lenalidomide enhances the biological activity of galiximab against non-Hogkin's lymphoma in vitro and in vivo. Blood 2007; 110(11 Part 1):Abstract #2353
  • Reddy NM, Hernandez-Ilizaliturri F, Roth M, Vaughan M, Deeb G, Czuczman MS. Lenalidomide enhances rituximab anti-tumor activity by inducing expansion, activation and tumor infiltration of Natural killer (NK) cells, as well as alters the tumor microenvironment and inhibits angiogenesis. Proceedings of the American Association for Cancer Research Annual Meeting 2007; 48:844-845
  • Reeder CB, Witzig TE, Vose JM, Zinzani PL, Buckstein R, Haioun C, Bouabdallah R, Polikoff J, Guo P, Ervin-Haynes A, Pietronigro D, Zeldis JB, Czuczman MS. The Efficacy and Safety of Lenalidomide Oral Monotherapy in Patients with Mantle Cell Lymphoma Previously Treated with Bortezomib: Pooled Data from Two Phase 11 Studies (NHL-002 and NHL-003). Blood 2008; 112(11):553
  • Reeder CB, Witzig TE, Zinzani PL, Vose JM, Buckstein R, Haioun C, Bouabdallah R, Polikoff J, Pietronigro D, Czuczman MS. Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: Results from an international study (NHL-003). Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #8569
  • Ritesh P, Pahuja S, Chavez J, Braddy W, Skipper M, Bernstein ZP, Chanan-Khan A, Ramanarayanan J, Czuczman MS, Hernandez-Ilizaliturri FJ. Correlation of surface expression of CD11b or CD32 in polymorphonuclear cells (PMNs) and CD69 in natural killer cells (NK) with progression-free survival (PFS) following chemoimmunotherapy with rituximab and liposomal doxorubicin (LD) in patients (pts) with relapsed or refractory B-cell lymphoma. Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #8583
  • Sher T, Miller KC, Ailawadhi S, Manfredi D, Wood M, Tan W, Wilding G, Liu H, Czuczman MS, Hernandez F, Hong F, Sood R, Soniwalla S, Lawrence W, ipd_10, Lee KP, Chanan-Khan A. Bortezomib in Combination with Pegylated Liposomal Doxorubicin and Thalidomide (VDT), An Effective Steroid Independent Regimen for Previously Untreated Multiple Myeloma Patients: Final Result of a Phase II Study. Blood 2009; 114(22):256
  • Siddiqui A, Lamonica DM, Gona J, Rehman F, Galantwicz P, Warner J, Czuczman M. Utility of the FDG-PET in low-grade non-Hodgkin's lymphoma (LGNHL). European journal of nuclear medicine and molecular imaging 2007; 34(Suppl. 2):S290
  • Tsai PC, Bangia N, Olejniczak S, Hernandez-Llizaliturri FJ, Czuczman M. The Acquirement of Rituximab Resistance Is Associated with a Global Downregulation of CD54 in B-Cell Lymphoma Cells: The Potential Role of Adhesion Molecules in Rituximab Anti-Tumor Activity. Blood 2008; 112(11):903-904
  • Tsai P-C, Hernandez-Ilizaliturri FJ, Olejniczak S, Knight J, Bangia N, Czuczman M. Effects of Interleukin 4 (IL-4) on CD20 expression in rituximab-sensitive (RSCL) and rituximab resistant cell lines (RRCL). Proceedings of the American Association for Cancer Research Annual Meeting 2007; 48:218
  • Tsai PC, Hernandez-Ilizaliturri FJ, Olejniczak SH, Naveen B, Czuczman MS. Modulation of CD20 expression in rituximab-sensitive (RSCL) and rituximab resistant cell lines (RRCL) using IL-4 and bryostatin-1. Blood 2007; 110(11 Part 1):Abstract #2619
  • Vinjamaram S, Hemandez-Ilizaliturri FJ, Retke S, Knight J, Czuczman MS. Targeting BH3-domain anti-apoptotic proteins with ABT-737 decreases DNA synthesis, induces cell death and sensitizes rituximab-sensitive and rituximab-resistant non-Hodgkin's lymphoma cell lines to the anti-tumor activity of chemotherapy agents. Blood 2007; 110(11 Part 2):418A (Abstract #1393)
  • Vose JM, Habermann T, Czuczman MS, Zinzani PL, Reeder CB, Tuscano J, Lossos IS, Pietronigros D, Ervin-Hayness A, Witzig T. Single-Agent Lenalidomide for Patients with Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma Who Had Received Prior Stem Cell Transplant. Blood 2009; 114(22):1056
  • Wilson W, O'Connor OO, Roberts AW, Czuczman M, Brown J, Xiong H, Xiong H, Chiu Y, Krivoshik A, Enschede S, Humerickhouse R. ABT-263 activity and safety in patients with relapsed or refractory lymphoid malignancies in particular chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #8574
  • Wilson WH, O'Connor O, Czuczman MS, LaCasce A, Gerecitano J, Leonard JP, Tulpule A, Xiong H, Chiu YL, Busman T, Knight RA, Enschede S, Krivoshik A, Humerickhouse R. Phase 1 Study of ABT-263, a Bcl-2 Family Inhibitor, in Relapsed or Refractory Lymphoid Malignancies. Blood 2008; 112(11):734
  • Wilson WH, O'Connor OA, Czuczman MS, LaCasce A, Gerecitano J, Leonard JP, Tulpule A, Xiong H, Chiu YL, Busman T, Enschede S, Krivoshik A, Humerickhouse R. Phase 1/2a Study of ABT-263 in Relapsed or Refractory Lymphoid Malignancies. Blood 2009; 114(22):682
  • Wilzig TE, Reeder CB, Polikoff J, Chowhan NM, Esseessee I, Greenberg R, Patel H, Vafai D, Wiernik PH, Ervin-Haynes A, Pietronigro D, Zeldis JB, Czuczman M. Initial results from an international study in relapsed/refractory aggressive non-Hodgkin's lymphoma to confirm the activity, safety and criteria for predicting response to lenalidomide monotherapy. Blood 2007; 110(11 Part 1):Abstract #2572
  • Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff J, Guo PS, Pietronigro D, Ervin-Haynes A, Czuczman MS. Durable Responses After Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory (R/R) Aggressive Non-Hodgkin's Lymphoma (a-NHL): Results From An International Phase 2 Study (CC-5013-NHL-003). Blood 2009; 114(22):668-669
  • Zinzani PL, Witzig TE, Vose JM, Reeder CB, Buckstein R, Haioun C, Bouabdallah R, Polikoff J, Guo PS, Ervin-Hayes A, Pietronigro D, Zeldis JB, Czuczman MS. Confirmation of the Efficacy and Safety of Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory Mantle-Cell Lymphoma: Results of An International Study (NHL-003). Blood 2008; 112(11):103
  • Chanan-Khan AA, Chitta K, Ersing N, Paulus A, Masood A, Sher T, Swaika A, Wallace PK, Mashtare TL Jr, Wilding G, Lee K, Czuczman MS, Borrello I, Bangia N. Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. British journal of haematology 2011; 155(4):457-467
  • Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, MacOn WR, Goy A, Witzig TE, Czuczman MS. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer 2011; 117(22):5058-5066
  • Barth MJ, Hernandez-Ilizaliturri FJ, Mavis C, Tsai PC, Gibbs JF, Deeb G, Czuczman MS. Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. British journal of haematology 2012; 156(4):490-498
  • Evens AM, Vanderplas A, LaCasce A, Crosby A, Nademanee A, Kaminski MS, Abel GA, Millenson M, Czuczman MS, Rodriguez MA, Niland J, Zelenetz AD, Gordon LI, Friedberg J. Outcomes with Autologous (Auto) and Allogeneic (Allo) Stem Cell Transplantation (SCT) for Relapsed/Refractory Follicular Lymphoma (FL) in the Post-Rituximab Era: A Comparative Analysis From the National Comprehensive Cancer Network (NCCN) Non-Hodgkin's Lymphoma (NHL) Outcomes Database Project. Blood 2011; 118(21):1756-1757
  • Fowler NH, Kahanic SP, Forero A, Munteanu MC, Davis GL, Brown P, Van Den Neste E, Offner FC, Bron D, Czuczman MS. Results of a Phase II Study with Bendamustine and Ofatumumab in Untreated Indolent B-Cell Non-Hodgkin's Lymphoma. Blood 2011; 118(21):353
  • LaCasce AS, Vandergrift JL, Rodriguez MA, Abel GA, Crosby AL, Czuczman MS, Nademanee AP, Blayney DW, Gordon LI, Millenson M, Vanderplas A, Lepisto EM, Zelenetz AD, Niland J, Friedberg JW. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood 2012; 119(9):2093-2099
  • Matasar MJ, Czuczman MS, Rodriguez MA, Fennessy M, Shea TC, Spitzer G, Lossos IS, Kharfan-Dabaja MA, Joyce R, Fayad L, Liao QM, Edvardsen K, Lisby S, Moskowitz CH. A Phase II Study of Ofatumumab in Combination with ICE or DHAP Chemotherapy in Relapsed or Refractory Aggressive B-Cell Lymphoma Prior to Autologous Stem Cell Transplantation (ASCT). Blood 2011; 118(21):437-438
  • Mavis C, Frys S, Gu J, Gibbs J, Czuczman MS, Hernandez-Ilizaliturri FJ. Entinostat, a Novel Histone Deacetylase (HiDAC) Inhibitor Enhances the Anti-Tumor Activity of Bortezomib (BTZ) in Rituximab-Chemotherapy Sensitive and Resistant Lymphoma Cell Lines. Blood 2011; 118(21):1594
  • Press OW, Unger JM, Rimsza LM, Friedberg J, LeBlanc M, Czuczman MS, Kaminski MS, Braziel RM, Maloney DG, Cheson BD, Miller TP, Fisher RI. A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy Plus Rituximab Vs. CHOP Chemotherapy Plus Iodine-131-Tositumomab for the Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphoma. Blood 2011; 118(21):48
  • Tsai PC, Hernandez-Ilizaliturri FJ, Bangia N, Olejniczak SH, Czuczman MS. Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma. Clinical cancer research 2012; 18(4):1039-1050
  • Abel GA, Vanderplas A, Rodriguez MA, Crosby AL, Czuczman MS, Niland JC, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, Lacasce AS. High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. Leukemia and lymphoma 2012; 53(6):1113-1116
  • Czuczman MS, Fayad L, Delwail V, Cartron G, Jacobsen E, Kuliczkowski K, Link BK, Pinter-Brown L, Radford J, Hellmann A, Gallop-Evans E, DiRienzo CG, Goldstein N, Gupta I, Jewell RC, Lin TS, Lisby S, Schultz M, Russell CA, Hagenbeek A. Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood 2012; 119(16):3698-3704
  • Czuczman MS, Hess G, Gadeberg OV, Pedersen LM, Goldstein N, Gupta I, Jewell RC, Lin TS, Lisby S, Strange C, Windfeld K, Viardot A. Chemoimmunotherapy with ofatumumab in combination with CHOP in previously untreated follicular lymphoma. British journal of haematology 2012; 157(4):438-445
  • Kumar A, Vanderplas A, Lacasce AS, Rodriguez MA, Crosby AL, Lepisto E, Czuczman MS, Nademanee A, Niland J, Gordon LI, Millenson M, Zelenetz AD, Friedberg JW, Abel GA. Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: Findings from a large national database. Cancer 2012; 118(11):2944-2951
  • Wilson WH, Jung S-H, Porcu P, Hurd D, Johnson J, Eric Martin S, Czuczman M, Lai R, Said J, Chadburn A, Jones D, Dunleavy K, Canellos G, Zelenetz AD, Cheson BD, Hsi ED. A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica 2012; 97(5):758-765
  • Barth MJ, Pendurti G, Mavis C, Czuczman N, Skitzki JJ, Hernandez-Ilizaliturri FJ, Czuczman MS. Preclinical activity of ofatumumab (OFA) in mantle cell lymphoma (MCL) in vitro, ex vivo, and in vivo models. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #e18537
  • Dawar R, Barth MJ, Mavis C, Skitzki JJ, Czuczman MS, Klener P, Hernandez-Ilizaliturri FJ. Evaluation of MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, as a novel targeted agent with single-agent antitumor activity in mantle cell lymphoma (MCL) and Hodgkin lymphoma preclinical models. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #e18539
  • Jitawatanarat P, Dawar R, Chittawatanarat K, Batty N, Czuczman MS, Hernandez-Ilizaliturri FJ. Alternating non-cross-resistant multiagent chemotherapy (ANCRC) and high-dose chemotherapy followed by autologous stem cell support (HDC-ASCS) in first remission to improve outcome in patients with T-cell lymphoma. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #e18538
  • Ailawadhi S, Miller KC, Depaolo D, Whitworth A, Brady W, Czuczman M, Bernstein ZP, Hernandez-Ilizaliturri F, Padmanabhan S, Chanan-Khan A. Fludarabine Plus Thalidomide as Frontline Therapy for Newly Diagnosed Patients With Chronic Lymphocytic Leukemia (CLL). Haematologica 2008; 93(Suppl. 1):0086
  • Brown J, Roberts A, Seymour JF, Wierda W, O'Connor O, Czuczman M, Xiong H, Enschede S, Krivoshik A, Wilson W. Ongoing phase 1 studies of ABT-263; pharmacokinetics, safety and anti-tumor activity in patients with relapsed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Annals of oncology 2008; 19(Suppl. 8):229
  • Haioun C, Czuczman MS, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Bouabdallah R, Polikoff J, Ervin-Haynes A, Witzig TE. Patients with relapsed or refractory diffuse large-B-cell lymphoma treated with oral lenalidomide monotherapy: Results from the international study NHL-003. Haematologica 2009; 94(Suppl. 2):0982
  • Haioun C, Reeder CB, Polikoff J, Chowhan NM, Esseessee I, Greenberg R, Ervin-Haynes A, Pietronigro D, Zeldis JB, Witzig TE, Czuczman MS. Results from an international study investigating the efficacy and safety of lenalidomide in relapsed or refractory aggressive non-Hodgkin's lymphoma. Haematologica 2008; 93(Suppl. 1):0399
  • Padmanabhan S, Block AW, Wallace P, Tan W, Nowak N, Varadarajan P, Barcos M, Hernandez F, Ketepalli S, Wilding G, Czuczman M, Chanan-Khan A. Concomitant z score and ZAP 70 along with ATM deletion identifies patients with poor survival from the RPCI Chronic Lymphocytic Leukemia Series: A correlation of treatment and survival of B-CLL patients with prognostic variables such as fish, ZAP70 expression, CGH. Haematologica 2008; 93(Suppl. 1):416 (Abstract #1053)
  • Sher T, Miller K, Patel M, Whitworth A, Musial L, Lawrence D, Padmanabhan S, Ailawadhi S, Wilding G, DePaolo D, Bangia N, Czuczman MS, Wallace PK, Lee KP, Khan AC. Lenalidomide associated tumor flare reaction correlates with clinical response in patients with relapsed or refractory B-cell chronic lymphocytic leukemia. Haematologica 2009; 94(Suppl. 2):0928
  • Wierda G, Roberts P, Brown R, Wilson H, O'Connor A, Czuczman S, Busman A, Xiong H, Krivoshik P, Enschede H. Pharmacokinetics, safety and anti-tumor activity of ABT-263 in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica 2009; 94(Suppl. 2):0350
  • Zinzani PL, Reeder CB, Witzig TE, Vose JM, Buckstein R, Haioun C, Bouabdalleh R, Polikoff J, Pietronigro D, Czuczman MS. Lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: Efficacy and safety results from an international study (NHL-003). Haematologica 2009; 94(Suppl. 2):0978
  • Czuczman MS, Leonard JP, Jung S, Johnson JL, Hsi ED, Byrd JC, Cheson BD. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. Annals of oncology 2012; 23(9):2356-2362